Simponi (Golimumab) Injection

Description

The U.S. Food and Drug Administration (FDA) has approved Simponi to treat the following conditions:

• Rheumatoid Arthritis (RA): for moderately to severely active RA in adults, used in combination with methotrexate.
• Psoriatic Arthritis (PsA): for active PsA in adults (alone or with methotrexate), and in patients 2 years of age and older with active PsA.
• Ankylosing Spondylitis (AS): for active AS in adults.
• Ulcerative Colitis (UC): for moderately to severely active UC in adults and pediatric patients weighing at least 33 pounds (15 kg) who have not responded well to conventional therapies or require ongoing steroid treatment.
• Polyarticular Juvenile Idiopathic Arthritis (pJIA): The intravenous formulation, Simponi Aria, is approved for active pJIA in patients 2 years of age and older.

Simponi works by targeting and blocking TNF-alpha, a protein in the body’s immune system that causes inflammation and joint damage. It helps reduce pain, stiffness, and swelling in the joints and can slow the progression of joint damage.

Which areas or states do you supply to?

Simponi (Golimumab) Injection is available in following cities in India – Mumbai, Delhi, Gurgaon, Noida, Bengaluru, Hyderabad, Ahmedabad, Chennai, Kolkata, Surat, Pune, Jaipur, Lucknow, Kanpur, Gurgaon, Punjab, Nagpur, Indore, Thane, Bhopal, Visakhapatnam, Pimpri-Chinchwad, Patna, Vadodara, Ghaziabad, Ludhiana, Agra, Nashik, Faridabad, Meerut, Rajkot, Kalyan-Dombivli, Vasai-Virar, Varanasi, Srinagar, Aurangabad, Dhanbad, Amritsar, Navi Mumbai, Prayagraj, Howrah, Ranchi, Jabalpur, Gwalior, Coimbatore, Vijayawada, Jodhpur, Madurai, Raipur, Kota, etc.

For large institutional or inter-state distribution, please contact our sales department for region-specific arrangements.